In addition to palbociclib, a recent study has revealed that THZ-1, a covalent inhibitor of CDK7, antagonizes GLI1 and GLI2 transcription, preventing the growth of SHH-driven MBs and SMO inhibitor-resistant human tumor cell lines in vivo and in vitro (Liu et al., 2019). Here, GLI2 is linked to neoplasm.